The impact of functionally high-risk disease in patients with R/R myeloma receiving late-line CAR-T
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2026-01-12
Просмотров: 12
Описание:
In this video, Hamza Hashmi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the association between functionally high-risk disease and inferior outcomes after CAR T-cell therapy for relapsed/refractory (R/R) multiple myeloma (MM), highlighting that while CAR T-cell therapy can overcome the negative prognostic impact of functionally high-risk disease when given in earlier lines of treatment, it may not do so as a late-line therapy. As a result of this, Dr Hashmi recommends that patients with functionally high-risk disease who progress within 24 months of their frontline therapy should be considered for CAR-T at first relapse. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
